ASCO Annual Meeting - American Society of Clinical Oncology Annual Meeting

Biosimilar trastuzumab antibody (MYL-1401O) comparable in efficacy and safety to targeted cancer drug in women with HER2-positive advanced breast cancer.

Patients receiving intraperitoneal and intravenous chemotherapy had progression-free survival of 59.3 months.

Capecitabine chemotherapy in combination with gemcitabine show median overall survival rate of 28 months.

Anaplastic glioma patients administered temozolomide after radiation, with or without concurrent temozolomide, saw a slower progression of the disease.

Precision medicine found to be associated with increased tumor reduction and progression-free survival.

Overall 3-year survival in patients with advanced melanoma taking pembrolizumab was 40%.

Family caregivers of patients with terminal cancers could benefit from early palliative care.

Patients with multiple myeloma receiving ASCT showed a 10% increase in tumor cell reduction.